TY - JOUR
T1 - Suprachoroidal space alterations following delivery of triamcinolone acetonide
T2 - Post-hoc analysis of the phase 1/2 HULK study of patients with diabetic macular edema
AU - Lampen, Shaun I.R.
AU - Khurana, Rahul N.
AU - Noronha, Glenn
AU - Brown, David M.
AU - Wykoff, Charles C.
N1 - Funding Information:
Originally submitted February 2, 2018. Revision received June 6, 2018. Accepted for publication August 3, 2018. This study was supported by a research grant from Clearside Biomedical (Alpharetta, GA). The funding organization had no role in the conduct of this research. Dr. Khurana has received grants and personal fees from Allergan, Regeneron, and Santen, as well as personal fees from Genetech, outside the submitted work. Dr. Noronha is an employee of Clearside Biomedical and has a patent related to the drug, CLS-TA, and to the method of suprachoroidal administration to treat inflammatory conditions pending. Dr. Brown has received grants and personal fees from ADverum, Alcon, Akkegro, Allergan, Apellis, Boehringer Ingelheim, Genentech, Heidelberg Engineering, Novartis, OHR, Ophthotech, Regeneron, Regenxbio, Roche, Santen, SciFluor, Taiwan Liposome, Tyrogenex, and Clearside Biomedical; grants from Aerpio, Alderya, Astellas, Aura, Bayer, Chiltern, GlaxoSmithKline, Iconic Therapeutics, INC Research, Johns Hopkins, NEI, Ora, Jaeb Center for Health Research, and pSivida; and personal fees from Chengdu Kanghong Biotechnology, Coda Therapeutics, Johnson and Johnson, Merck, Notal Vision, Optos, Optovue, Pfizer, Samsung Bioepis, Senju Pharmaceuticals, Stealth BioTherapeutics, Thrombogenics, and Zeiss outside the submitted work. Dr. Wykoff has received grants from Adverum Biotechnologies, Aerpio Therapeutics, Aldeyra Therapeutics, Alimera Sciences, Allegro Ophthalmics, Apellis Pharmaceutical, Astel-las Pharma, Aura Biosciences, Boehrigner Ingelheim, Chiltern International, GlaxoSmithKline, Heidelberg Engineering, Iconic Therapeutics, INC Research, Johns Hopkins, NEI, Novartis International AG, Ophthotech Corportation, OHR Pharmaceutical, Regenexbio, Ora, pSivida, SciFluor Life Sciences, Taiwan Liposome Company, and Tyrogenex; grants and personal fees from Alcon Laboratories, Allergan, Genentech, Regeneron, Roche, Santen, and Clearside Biomedical; and personal fees from Alnylam Pharmaceuticals, Atheneum Partners, Bayer AG, Consultants, CORCEPT, Destum Partners, D.O.R.C., Hexal AG, k2c Medical Communications, Notal Vision, Novo Nordisk, ONL Therapeutics, Prime Education, personal fees from System Analytic, ThromboGenics NV, and Valeant Pharmaceuticals outside the submitted work. Dr. Lampen reports no relevant financial disclosures. Address correspondence to Charles C. Wykoff, MD, PhD, 6560 Fannin Street, Suite 750, Houston, TX 77030; email: ccwmd@houstonretina.com. doi: 10.3928/23258160-20180831-07
Publisher Copyright:
© 2018 Slack Incorporated. All rights reserved.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - BACKGROUND AND OBJECTIVE: To study anatomic changes in the suprachoroidal space (SCS) following suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension. PATIENTS AND METHODS: Eyes with diabetic macular edema receiving CLS-TA were imaged serially using anterior segment spectral-domain optical coherence tomography to examine the SCS. RESULTS: At the final imaging session, the SCS was not significantly different in study eyes (n = 14; 8.4 µm) compared to fellow eyes (n = 10; 8.1 µm; P = .698). Two eyes were imaged immediately before and 30 minutes after suprachoroidal injections; in these eyes, mean suprachoroidal width increased significantly following CLS-TA injection, 9.9 µm to 75.1 µm (P < .001), and subsequently returned to 14.9 µm 1 month after the final injection (P = .221). CONCLUSION: Suprachoroidal CLS-TA injection caused a measurable increase in the SCS, which returned to preinjection levels by 1 month following injection with no apparent lasting impact on SCS anatomy.
AB - BACKGROUND AND OBJECTIVE: To study anatomic changes in the suprachoroidal space (SCS) following suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension. PATIENTS AND METHODS: Eyes with diabetic macular edema receiving CLS-TA were imaged serially using anterior segment spectral-domain optical coherence tomography to examine the SCS. RESULTS: At the final imaging session, the SCS was not significantly different in study eyes (n = 14; 8.4 µm) compared to fellow eyes (n = 10; 8.1 µm; P = .698). Two eyes were imaged immediately before and 30 minutes after suprachoroidal injections; in these eyes, mean suprachoroidal width increased significantly following CLS-TA injection, 9.9 µm to 75.1 µm (P < .001), and subsequently returned to 14.9 µm 1 month after the final injection (P = .221). CONCLUSION: Suprachoroidal CLS-TA injection caused a measurable increase in the SCS, which returned to preinjection levels by 1 month following injection with no apparent lasting impact on SCS anatomy.
UR - http://www.scopus.com/inward/record.url?scp=85053507318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053507318&partnerID=8YFLogxK
U2 - 10.3928/23258160-20180831-07
DO - 10.3928/23258160-20180831-07
M3 - Article
C2 - 30222804
AN - SCOPUS:85053507318
SN - 2325-8160
VL - 49
SP - 692
EP - 697
JO - Ophthalmic Surgery Lasers and Imaging Retina
JF - Ophthalmic Surgery Lasers and Imaging Retina
IS - 9
ER -